Literature DB >> 16388508

A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).

Monique J Roobol1, Fritz H Schröder, Ries Kranse.   

Abstract

BACKGROUND: The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA>or=3.0 ng/ml as biopsy indication.
MATERIALS AND METHODS: We compared predictors by means of descriptive statistics and logistic regression analysis in men (55-75 years) biopsied in either the 1st or 2nd screening round of ERSPC Rotterdam (interval 4 years).
RESULTS: Positive predictors for biopsy outcome in both screening rounds were an increased PSA level in the absence of a previous negative biopsy (PrevNB), DRE and TRUS suspicious and a positive family history (PFH). A higher than median prostate volume was a consistent negative predictor. Having had a PrevNB at initial screening strongly reduced the chance of cancer detection at repeat screening and in addition canceled the predictive potential of PSA.
CONCLUSION: If "detecting prostate cancer efficiently" were the aim, this study indicates that a "PSA only based biopsy threshold" may be replaced by another criterion incorporating, e.g., DRE, TRUS and prostate volume in men who were biopsied in the preceding 4 year interval. Prostate 66:604-612, 2006. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388508     DOI: 10.1002/pros.20352

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Authors:  Hans Lilja; Angel M Cronin; Anders Dahlin; Jonas Manjer; Peter M Nilsson; James A Eastham; Anders S Bjartell; Peter T Scardino; David Ulmert; Andrew J Vickers
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

3.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

Review 4.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

5.  Algorithms, nomograms and the detection of indolent prostate cancer.

Authors:  Monique J Roobol
Journal:  World J Urol       Date:  2008-06-07       Impact factor: 4.226

6.  The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Authors:  Moniek M Vedder; Esther W de Bekker-Grob; Hans G Lilja; Andrew J Vickers; Geert J L H van Leenders; Ewout W Steyerberg; Monique J Roobol
Journal:  Eur Urol       Date:  2014-08-26       Impact factor: 20.096

7.  A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.

Authors:  A Gupta; M J Roobol; C J Savage; M Peltola; K Pettersson; P T Scardino; A J Vickers; F H Schröder; H Lilja
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Authors:  Monique J Roobol; F H Schröder; Jonas Hugosson; J Stephen Jones; Michael W Kattan; Eric A Klein; Freddie Hamdy; David Neal; Jenny Donovan; Dipen J Parekh; Donna Ankerst; George Bartsch; Helmut Klocker; Wolfgang Horninger; Amine Benchikh; Gilles Salama; Arnauld Villers; Stephen J Freedland; Daniel M Moreira; Andrew J Vickers; Hans Lilja; Ewout W Steyerberg
Journal:  World J Urol       Date:  2011-12-28       Impact factor: 4.226

9.  Population-based Prostate Cancer Screening in Kazakhstan.

Authors:  Yevgeniy Ishkinin; Alma Zhylkaidarova; Nurzhan Nurgaliyev; Elmira Auyezova; Ainash Oshibayeva; Nadezhda Gorbunova
Journal:  Iran J Public Health       Date:  2017-07       Impact factor: 1.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.